VAREX IMAGING (VREX) Exceeds Expectations in Q4 Earnings and Revenue
Earnings Performance: VAREX IMAGING reported quarterly earnings of $0.37 per share, significantly exceeding the Zacks Consensus Estimate of $0.18, marking a 105.56% earnings surprise. The company also surpassed revenue expectations with $228.9 million, up from $205.7 million a year ago.
Stock Outlook: Despite strong earnings performance, VAREX IMAGING shares have declined by 21.7% this year, underperforming the S&P 500's 13.4% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Industry Context: The Medical - Products industry, to which VAREX IMAGING belongs, is currently ranked in the bottom 30% of Zacks industries, suggesting potential challenges ahead. The performance of VAREX IMAGING may be influenced by broader industry trends.
Future Earnings Estimates: The consensus EPS estimate for the upcoming quarter is $0.21, with projected revenues of $207.65 million. Investors are advised to monitor changes in earnings estimates and industry outlooks, as these factors can significantly impact stock performance.
Trade with 70% Backtested Accuracy
Analyst Views on VREX
About VREX
About the author

- Stable Revenue Performance: Varex Imaging reported Q2 revenue of $216 million, aligning with guidance, with a 2% increase in medical revenue driven by strong CT sales, indicating stability in both medical and industrial sectors despite some softness in industrial performance.
- Strong Gross Margin: The non-GAAP gross margin stood at 34%, at the high end of guidance, with non-GAAP EPS of $0.21, reflecting effective cost control amidst rising raw material prices, showcasing the company's resilience in maintaining profitability.
- Successful Debt Restructuring: The company completed debt refinancing, resulting in reduced outstanding debt and lower annual interest expenses, enhancing its capital structure and providing greater flexibility for future investments and growth initiatives.
- Optimistic Future Outlook: Full fiscal year 2026 revenue is expected to range between $860 million and $880 million, with Q3 revenue guidance set between $210 million and $225 million, demonstrating the company's confidence in future growth despite facing some cost and logistics challenges.
Q2 Adjusted EPS: VAREX Imaging reported an adjusted earnings per share (EPS) of USD 0.21 for the second quarter.
Comparison with Estimates: This EPS figure matches the estimates provided by IBES, which also projected an EPS of USD 0.21.
- Earnings Release Schedule: Varex Imaging Corporation will announce its unaudited financial results for Q2 of fiscal year 2026 after market close on May 7, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Details: Following the earnings release, Varex will host a conference call at 3:00 PM Mountain Time, allowing investors to participate via 877-524-8416 (U.S.) or 412-902-1028 (non-U.S.), enhancing investor engagement and communication.
- Webcast and Replay Availability: The conference call will be webcast live and accessible on the company's website, with a replay available from May 7 to May 21, ensuring broad dissemination of information and transparency for stakeholders.
- Company Background: Varex Imaging Corporation is a leading manufacturer of X-ray imaging components with over 70 years of innovation, whose products are utilized in medical, industrial, and security imaging applications, underscoring its significant market presence.
- Credit Agreement Overview: Varex Imaging has entered into a $490 million Credit and Guaranty Agreement on March 13, 2026, which includes a $350 million secured term loan and a $100 million secured revolving credit facility, maturing in 2031, thereby enhancing the company's financial flexibility.
- Debt Redemption Plan: The company plans to redeem $368 million of its 7.875% Senior Secured Notes on March 16, 2026, using funds from the new credit agreement, which is expected to reduce annual cash interest expenses by over $7 million, significantly improving its financial position.
- Interest Rate Management Strategy: Varex has entered into an interest rate swap that effectively fixes the variable SOFR rate at 3.65%, with an applicable margin set at 2.50%, which will help lower financing costs and enhance future free cash flow generation capabilities.
- Strategic Investment Direction: The CFO stated that this financing will support continued investment in the core business while prioritizing long-term shareholder value, demonstrating the company's confidence and commitment to future growth.
- Investor Conference Schedule: Varex Imaging announced its participation in Oppenheimer's 36th Annual Healthcare, MedTech & Services Virtual Conference on March 17, 2025, at 10:40 AM ET, and the Sidoti Small Cap Virtual Conference on March 18, 2026, at 1:00 PM ET, showcasing the company's innovations and market outlook in medical imaging.
- Webcast Access: Investors can access the conferences via the company's website or provided webcast links, ensuring transparent communication with investors and enhancing market confidence.
- Company Background: Varex Imaging is a leading innovator in X-ray imaging components with over 70 years of successful innovation history, with products widely used in medical, industrial, and security imaging, demonstrating the company's deep technological expertise.
- Global Workforce Distribution: Varex employs approximately 2,400 people across North America, Europe, and Asia, showcasing its global operational capabilities and market reach, further solidifying its leadership position in the imaging industry.









